Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

COMPLETED

Identifier: CI-TRIAL-00087374
Entity page: /trial/NCT04256707 ↗
Edges: 10

Neighbours: 3 cancers4 drugs
Drawn: 7 of 7 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment condition of …CONDITION_OFderived3 of 3
← condition of	Colorectal Neoplasm registry condition “Other Solid Tumors” mapped PROBABILISTIC	—	—	Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
← condition of	Lung Non-Small Cell Carcinoma registry condition “Non-Small Cell Lung Carcinoma (NSCLC)” mapped ALIAS

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Docetaxelsmall molecule registry intervention “Docetaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	FOLFIRI Regimen registry intervention “FOLFIRI” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Selinexorsmall molecule registry intervention “Selinexor 100 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Selinexorsmall molecule registry intervention “Selinexor 40 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Selinexorsmall molecule registry intervention “Selinexor 60 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Selinexorsmall molecule registry intervention “Selinexor 80 mg” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Docetaxelsmall molecule

registry intervention “Docetaxel” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

FOLFIRI Regimen

registry intervention “FOLFIRI” (DRUG) mapped ALIAS

—